EU regulators approve first targeted drug for interstited large cell lymphoma - Takeda anti-CD30 ADC drug Adcetris

European regulators have approved Takeda's target CD30 antibody drug adcetris (ADC) Adcetris (Brentuximab vedotin) in conjunction with CHP (cyclophosphamide, amycin, pernithe) for previously untreated adult patients with systemictrans large cell lymphoma (sALCL)Adcetris is the first and only first-line targeted therapy approved for the treatment of sALCL in decades, offering new treatment options for patients with this type of peripheral T-cell lymphoma (PTCL)the approval was based on the results of the PHASE II II study, and adcetris joint CHP reached the main end of the experiment compared to the standard treatment of CHOP (cyclophosphamide, amycin, changchun xinylene, strong pine)according to the company, the safety of the combined drugs observed in the trial sylweded with standard treatment and was consistent with the established safetyDr Eva Domingo-Domenech said: 'Clinical outcomes in patients with sALCL tend to be poor, and many patients are unable to achieve long-term survival or remission through standard care'
' ECHELON-2 data show that patients treated with Adcetris combined CHP receiveconsidered considerable results compared to standard treatment, while maintaining considerable safety'